Literature DB >> 10098746

Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes.

T D de Gruijl1, H J Bontkes, F Peccatori, M P Gallee, T J Helmerhorst, R H Verheijen, J Aarbiou, W M Mulder, J M Walboomers, C J Meijer, N van de Vange, R J Scheper.   

Abstract

Lymphocytic infiltrate is often present in cervical cancer lesions, possibly reflecting an ongoing, but ineffective, immune response to the tumour. Recently, evidence has accumulated for systemically impaired T-cell functions in cancer patients, associated with decreased expression of signal-transducing zeta (zeta) chain dimer molecules on circulating T-cells and NK-cells. Here, we report on the intralesional down-regulation of zeta chain expression on T-cells in cervical carcinoma. Paraffin-embedded or snap-frozen sections from 24 different cervical cancer specimens were studied. Paraffin-embedded tumour-positive (n = 7) and tumour-negative (n = 15) pelvic lymph nodes were also included in the study. Immunostaining was performed on consecutive sections with antibodies specific for CD3-epsilon or the CD3-associated zeta chain dimer. Antigen retrieval by sodium citrate/microwave treatment was essential for zeta staining of paraffin sections. The amount of zeta positive cells was quantitated and related to the number of CD3-epsilon+ cells in corresponding tumour areas. Of the 24 cervical cancer specimens studied, zeta chain dimer expression was reduced in seven cases and strongly reduced in the other 17 samples. In tonsil control sections, CD3-epsilon and CD3-zeta were always co-expressed in almost equal numbers. Also, both tumour-negative and -positive lymph nodes showed zeta chain expression which equalled that of CD3-epsilon expression. These data indicate that a decreased expression of signal-transducing zeta molecules on tumour-infiltrating T-cells is frequent in cervical cancer. The apparently unimpaired zeta chain expression within draining lymph nodes suggests that local tumour-derived factors at the primary site are instrumental in zeta chain down-regulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098746      PMCID: PMC2362225          DOI: 10.1038/sj.bjc.6690179

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

Review 1.  Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.

Authors:  S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-11-20       Impact factor: 13.506

Review 2.  The host-tumor immune conflict: from immunosuppression to resistance and destruction.

Authors:  S Chouaib; C Asselin-Paturel; F Mami-Chouaib; A Caignard; J Y Blay
Journal:  Immunol Today       Date:  1997-10

3.  Sequential development of structural and functional alterations in T cells from tumor-bearing mice.

Authors:  M R Correa; A C Ochoa; P Ghosh; H Mizoguchi; L Harvey; D L Longo
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

4.  Lack of granzyme expression in T lymphocytes indicates poor cytotoxic T lymphocyte activation in human papillomavirus-associated cervical carcinomas.

Authors:  F.V. Cromme; J.M.M. Walboomers; J.W. Van Oostveen; M.J. Stukart; T.D. De Gruijl; J.A. Kummer; A.M. Leonhart; T.J.M. Helmerhorst; C.J.L.M. Meijer
Journal:  Int J Gynecol Cancer       Date:  1995-09       Impact factor: 3.437

5.  T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.

Authors:  W M Mulder; E Bloemena; M J Stukart; J A Kummer; J Wagstaff; R J Scheper
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

6.  Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function.

Authors:  E Tartour; S Latour; C Mathiot; N Thiounn; V Mosseri; I Joyeux; C D D'Enghien; R Lee; B Debre; W H Fridman
Journal:  Int J Cancer       Date:  1995-10-09       Impact factor: 7.396

7.  T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.

Authors:  T D de Gruijl; H J Bontkes; M J Stukart; J M Walboomers; A J Remmink; R H Verheijen; T J Helmerhorst; C J Meijer; R J Scheper
Journal:  J Gen Virol       Date:  1996-09       Impact factor: 3.891

8.  Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer.

Authors:  K Kono; M E Ressing; R M Brandt; C J Melief; R K Potkul; B Andersson; M Petersson; W M Kast; R Kiessling
Journal:  Clin Cancer Res       Date:  1996-11       Impact factor: 12.531

9.  Alterations in T cell receptor and signal transduction molecules in melanoma patients.

Authors:  A H Zea; B D Curti; D L Longo; W G Alvord; S L Strobl; H Mizoguchi; S P Creekmore; J J O'Shea; G C Powers; W J Urba
Journal:  Clin Cancer Res       Date:  1995-11       Impact factor: 12.531

10.  Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.

Authors:  H Nakagomi; M Petersson; I Magnusson; C Juhlin; M Matsuda; H Mellstedt; J L Taupin; E Vivier; P Anderson; R Kiessling
Journal:  Cancer Res       Date:  1993-12-01       Impact factor: 12.701

View more
  4 in total

Review 1.  Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia.

Authors:  Kirvis Torres-Poveda; Margarita Bahena-Román; Claudia Madrid-González; Ana I Burguete-García; Víctor Hugo Bermúdez-Morales; Oscar Peralta-Zaragoza; Vicente Madrid-Marina
Journal:  World J Clin Oncol       Date:  2014-10-10

2.  CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients.

Authors:  Cinthya E Díaz-Benítez; Karla R Navarro-Fuentes; Jacqueline A Flores-Sosa; Janet Juárez-Díaz; Felipe J Uribe-Salas; Edgar Román-Basaure; Ludwig E González-Mena; Patricia Alonso de Ruíz; Guillermina López-Estrada; Alfredo Lagunas-Martínez; Victor H Bermúdez-Morales; Juan M Alcocer-González; Jesús Martínez-Barnetche; Rogelio Hernández-Pando; Yvonne Rosenstein; José Moreno; Vicente Madrid-Marina
Journal:  J Clin Immunol       Date:  2009-03-04       Impact factor: 8.317

3.  Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development.

Authors:  E Guzmán-Olea; V H Bermúdez-Morales; O Peralta-Zaragoza; K Torres-Poveda; V Madrid-Marina
Journal:  J Oncol       Date:  2011-12-19       Impact factor: 4.375

4.  Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients.

Authors:  D D Taylor; D P Bender; J Stanson; T L Whiteside
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.